- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 929840, 5 pages
TET2 Mutations in Ph-Negative Myeloproliferative Neoplasms: Identification of Three Novel Mutations and Relationship with Clinical and Laboratory Findings
1Bleeding and Thrombotic Disorders Unit, Department of Hematology, Ospedale Civile dello “Spirito Santo”, 65124 Pescara, Italy
2Atherosclerosis and Thrombosis Unit, IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, Italy
3Laboratory of Molecular Biology, Department of Hematology, Ospedale Civile dello “Spirito Santo”, 65124 Pescara, Italy
4Department of Medical Genetics, Foggia University, 71100 Foggia, Italy
Received 2 April 2013; Accepted 9 May 2013
Academic Editor: Luca Arcaini
Copyright © 2013 Andrea Patriarca et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. Tefferi and W. Vainchenker, “Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies,” Journal of Clinical Oncology, vol. 29, no. 5, pp. 573–582, 2011.
- O. Abdel-Wahab, A. Mullally, C. Hedvat et al., “Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies,” Blood, vol. 114, no. 1, pp. 144–147, 2009.
- F. Delhommeau, S. Dupont, V. Della Valle, et al., “Mutation in TET2 in myeloid cancers,” New England Journal of Medicine, vol. 360, pp. 2289–2301, 2009.
- L. Couronné, E. Lippert, J. Andrieux et al., “Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias,” Leukemia, vol. 24, no. 1, pp. 201–203, 2010.
- S. M. C. Langemeijer, R. P. Kuiper, M. Berends et al., “Acquired mutations in TET2 are common in myelodysplastic syndromes,” Nature Genetics, vol. 41, no. 7, pp. 838–842, 2009.
- A. Tefferi, A. Pardanani, K. H. Lim et al., “TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis,” Leukemia, vol. 23, no. 5, pp. 905–911, 2009.
- A. Tefferi, R. L. Levine, K. H. Lim et al., “Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates,” Leukemia, vol. 23, no. 5, pp. 900–904, 2009.
- A. Tefferi, K. H. Lim, O. Abdel-Wahab et al., “Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML,” Leukemia, vol. 23, no. 7, pp. 1343–1345, 2009.
- O. Abdel-Wahab, “Genetics of the myeloproliferative neoplasms,” Current Opinion in Hematology, vol. 18, pp. 117–123, 2011.
- A. Tefferi and J. W. Vardiman, “Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms,” Leukemia, vol. 22, no. 1, pp. 14–22, 2008.
- A. Patriarca, F. Pompetti, R. Malizia et al., “Is the absence of JAK2V617F mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients,” Blood Transfusion, vol. 8, no. 1, pp. 21–27, 2010.
- F. Nguyen-Khac, C. Lesty, V. Eclache et al., “Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations,” Genes Chromosomes and Cancer, vol. 49, no. 10, pp. 919–927, 2010.
- C. Saint-Martin, G. Leroy, F. Delhommeau et al., “Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms,” Blood, vol. 114, no. 8, pp. 1628–1632, 2009.
- O. Kosmider, V. Gelsi-Boyer, M. Ciudad et al., “TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia,” Haematologica, vol. 94, no. 12, pp. 1676–1681, 2009.
- A. Kohlmann, H. U. Klein, S. Weissmann, et al., “The Interlaboratory Robustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories,” Leukemia, vol. 25, pp. 1840–1848, 2011.
- M. T. Voso, E. Fabiani, A. Piciocchi, et al., “Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine,” Leukemia, vol. 25, pp. 1910–1913, 2011.
- M. Ko, Y. Huang, A. M. Jankowska et al., “Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2,” Nature, vol. 468, no. 7325, pp. 839–843, 2010.
- D. A. Pollyea, A. Raval, B. Kusler, J. R. Gotlib, A. A. Alizadeh, and B. S. Mitchell, “Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors,” Journal of Hematology & Oncology, vol. 29, pp. 157–160, 2011.
- H. Szpurka, A. M. Jankowska, H. Makishima et al., “Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations,” Leukemia Research, vol. 34, no. 8, pp. 969–973, 2010.
- A. M. Jankowska, H. Szpurka, R. V. Tiu et al., “Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms,” Blood, vol. 113, no. 25, pp. 6403–6410, 2009.